Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Hepatitis

Free Subscription 15.04.2019 1 Ann Intern Med 1 Clin Infect Dis 4 Eur J Gastroenterol Hepatol 1 Gastroenterol Hepatol 1 Gastroenterology 1 Gut 2 Hepatology 1 Int J STD AIDS 5 J Hepatol 5 J Infect Dis 1 J Med Virol 6 J Viral Hepat 3 Lancet Gastroenterol Hepatol 2 MMWR Morb Mortal Wkly Rep 3 PLoS One 1 Proc Natl Acad Sci U S A 1 Science 1 Vaccine

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Ann Intern Med

1. AKIYAMA MJ, Norton BL, Arnsten JH, Agyemang L, et al
   Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial.
   Ann Intern Med. 2019 Apr 9. pii: 2730524. doi: 10.7326/M18-1715.
   PubMed     Text format     Abstract available
   
   

   
   Clin Infect Dis

2. BUTT AA, Yan P, Aslam S, Shaikh OS, et al
   Hepatitis C Virus Treatment with Directly Acting Agents Reduces the Risk of Incident Diabetes - Results from ERCHIVES.
   Clin Infect Dis. 2019 Apr 12. pii: 5448895. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   

   
   Eur J Gastroenterol Hepatol

3. POST G, Shalev N, Baumgarten A, Shimakawa Y, et al
   Indication for treatment and severity of disease in treatment-naive patients with chronic hepatitis B virus infection.
   Eur J Gastroenterol Hepatol. 2019 Apr 5. doi: 10.1097/MEG.0000000000001409.
   PubMed     Text format     Abstract available
   
   
4. ASHHAB AA, Rodin H, Powell J, Debes JD, et al
   Impact of immigration in presentation and outcomes of hepatocellular carcinoma in the USA.
   Eur J Gastroenterol Hepatol. 2019;31:24-28.
   PubMed     Text format     Abstract available
   
   
5. SORIANO V, Aguilera A, Gonzalez R, Gomez-Gallego F, et al
   Occult hepatitis B and HIV infection.
   Eur J Gastroenterol Hepatol. 2019 Apr 8. doi: 10.1097/MEG.0000000000001417.
   PubMed     Text format     Abstract available
   
   
6. EMORI CT, Uehara SNO, Carvalho-Filho RJ, Amaral AC, et al
   Changing pattern of chronic hepatitis C in renal transplant patients over 20 years.
   Eur J Gastroenterol Hepatol. 2019 Apr 5. doi: 10.1097/MEG.0000000000001404.
   PubMed     Text format     Abstract available
   
   

   
   Gastroenterol Hepatol

7. REVUELTO ARTIGAS T, Betriu Bars A, Zaragoza Velasco N, Gomez Arbones X, et al
   Antiviral treatment does not improve subclinical atheromatosis in patients with chronic hepatitis caused by hepatitis C virus.
   Gastroenterol Hepatol. 2019 Apr 2. pii: S0210-5705(19)30049.
   PubMed     Text format     Abstract available
   
   

   
   Gastroenterology

8. LUPBERGER J, Croonenborghs T, Roca Suarez AA, Van Renne N, et al
   Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of HCV-infected Cells and Liver to Identify Pathways Associated With Disease Development.
   Gastroenterology. 2019 Apr 9. pii: S0016-5085(19)35670.
   PubMed     Text format     Abstract available
   
   

   
   Gut

9. SHEN DT, Ji DZ, Chen HY, Goyal H, et al
   Hepatitis D: not a rare disease anymore: global update for 2017-2018.
   Gut. 2019 Apr 9. pii: gutjnl-2019-318691. doi: 10.1136/gutjnl-2019-318691.
   PubMed     Text format    
   
   

   
   Hepatology

10. JENSEN SB, Fahnoe U, Pham LV, Serre S, et al
    Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants.
    Hepatology. 2019 Apr 9. doi: 10.1002/hep.30647.
    PubMed     Text format     Abstract available
    
    
11. MARTIN P
    Immunetolerant Hepatitis B: Maybe a misnomer but still hard to treat.
    Hepatology. 2019 Apr 9. doi: 10.1002/hep.30654.
    PubMed     Text format     Abstract available
    
    

    
    Int J STD AIDS

12. SIMONCINI GM, Oyola-Jimenez J, Singleton D, Volgraf J, et al
    HIV and HCV screening among trauma patients.
    Int J STD AIDS. 2019 Apr 8:956462419829590. doi: 10.1177/0956462419829590.
    PubMed     Text format     Abstract available
    
    

    
    J Hepatol

13. MOUNA L, Rossignol E, Tateo M, Coilly A, et al
    Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence: Prophylaxis makes the difference.
    J Hepatol. 2019 Apr 6. pii: S0168-8278(19)30136.
    PubMed     Text format    
    
    
14. CABIBBO G, Celsa C, Calvaruso V, Petta S, et al
    Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    J Hepatol. 2019 Apr 5. pii: S0168-8278(19)30221.
    PubMed     Text format     Abstract available
    
    
15. KIM SU, Seo YS, Lee HA, Kim MN, et al
    A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naive chronic hepatitis B in the Republic of Korea.
    J Hepatol. 2019 Apr 5. pii: S0168-8278(19)30222.
    PubMed     Text format     Abstract available
    
    
16. RAMOS-CASALS M, Zignego AL, Ferri C, Brito-Zeron P, et al
    Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection.
    J Hepatol. 2017 Feb 17. pii: S0168-8278(17)30105.
    PubMed     Text format     Abstract available
    
    
17. KOLLY P, Waidmann O, Vermehren J, Moreno C, et al
    Hepatocellular Carcinoma Recurrence after Direct Antiviral Agent Treatment: a European Multicentre Study.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32150.
    PubMed     Text format    
    
    

    
    J Infect Dis

18. DOU Y, van Montfoort N, van den Bosch A, de Man RA, et al
    HBV-Derived Synthetic Long Peptide Can Boost CD4+ and CD8+ T-Cell Responses in Chronic HBV Patients Ex Vivo.
    J Infect Dis. 2018;217:827-839.
    PubMed     Text format     Abstract available
    
    
19. TALAL AH, Dumas EO, Bauer B, Rejman RM, et al
    Hepatic Pharmacokinetics and Pharmacodynamics with Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage.
    J Infect Dis. 2017 Sep 27. pii: 4210613. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
20. BOPPANA SB, Britt WJ, Fowler K, Hutto SC, et al
    Pathogenesis of Non-Zika Congenital Viral Infections.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available
    
    
21. HUANG CF, Hung CH, Cheng PN, Bair MJ, et al
    An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for treatment-naive chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resistance-associated subst
    J Infect Dis. 2019 Apr 8. pii: 5430846. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
22. DOUGLAS MW, Tay ES, Eden JS, George J, et al
    Hepatitis C Virus Genotype 8 - successful treatment with sofosbuvir/velpatasvir.
    J Infect Dis. 2019 Apr 8. pii: 5431216. doi: 10.1093.
    PubMed     Text format    
    
    

    
    J Med Virol

23. JACKSON K, Holgate T, Tekoaua R, Nicholson S, et al
    Evaluation of dried blood spots for hepatitis B and D serology and nucleic acid testing.
    J Med Virol. 2019 Apr 12. doi: 10.1002/jmv.25485.
    PubMed     Text format     Abstract available
    
    

    
    J Viral Hepat

24. WEN B, Zhang J, Liu W, Tang P, et al
    HBV coinfection with HCV alters circulating Tfh cell distribution and impairs HCV neutralizing antibody responses.
    J Viral Hepat. 2019 Apr 10. doi: 10.1111/jvh.13106.
    PubMed     Text format     Abstract available
    
    
25. DI BISCEGLIE AM, King WC, Lisker-Melman M, Khalili M, et al
    Age, race and viral genotype are associated with the prevalence of Hepatitis B e antigen in children and adults with chronic Hepatitis B.
    J Viral Hepat. 2019 Apr 11. doi: 10.1111/jvh.13104.
    PubMed     Text format     Abstract available
    
    
26. WEI L, Pavlovic V, Bansal AT, Chen X, et al
    Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B.
    J Viral Hepat. 2019 Apr 10. doi: 10.1111/jvh.13107.
    PubMed     Text format     Abstract available
    
    
27. CARABALLO CORTES K, Osuch S, Perlejewski K, Pawelczyk A, et al
    Expression of programmed cell death protein 1 (PD-1) and T cell immunoglobulin and mucin domain-containing molecule-3 (Tim-3) on peripheral blood CD4+CD8+ double positive T cells in patients with chronic hepatitis C virus (HCV) infection and in subjec
    J Viral Hepat. 2019 Apr 10. doi: 10.1111/jvh.13108.
    PubMed     Text format     Abstract available
    
    
28. TAMAKI N, Higuchi M, Kurosaki M, Kirino S, et al
    Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct acting antivirals.
    J Viral Hepat. 2019 Apr 11. doi: 10.1111/jvh.13103.
    PubMed     Text format     Abstract available
    
    
29. BACK D, Belperio P, Bondin M, Negro F, et al
    Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection and Psychiatric Disorders: An Integrated Analysis.
    J Viral Hepat. 2019 Apr 12. doi: 10.1111/jvh.13110.
    PubMed     Text format     Abstract available
    
    

    
    Lancet Gastroenterol Hepatol

30. SONNEVELD MJ, Brouwer WP, Chan HL, Piratvisuth T, et al
    Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study.
    Lancet Gastroenterol Hepatol. 2019 Apr 8. pii: S2468-1253(19)30087.
    PubMed     Text format     Abstract available
    
    
31. LAZARUS JV, Palayew A, van Damme P, Hendrickx G, et al
    Eliminating hepatitis C in Europe.
    Lancet Gastroenterol Hepatol. 2019;4:335-336.
    PubMed     Text format    
    
    
32. TSENG TC, Shih YF, Liu CJ
    A simple non-invasive test for ruling out cirrhosis in chronic hepatitis B.
    Lancet Gastroenterol Hepatol. 2019 Apr 8. pii: S2468-1253(19)30118.
    PubMed     Text format    
    
    

    
    MMWR Morb Mortal Wkly Rep

33. BRENNAN J, Moore K, Sizemore L, Mathieson SA, et al
    Notes from the Field: Acute Hepatitis A Virus Infection Among Previously Vaccinated Persons with HIV Infection - Tennessee, 2018.
    MMWR Morb Mortal Wkly Rep. 2019;68:328-329.
    PubMed     Text format    
    
    
34. WILSON E, Hofmeister MG, McBee S, Briscoe J, et al
    Notes from the Field: Hepatitis A Outbreak Associated with Drug Use and Homelessness - West Virginia, 2018.
    MMWR Morb Mortal Wkly Rep. 2019;68:330-331.
    PubMed     Text format    
    
    

    
    PLoS One

35. RAJAMOORTHY Y, Radam A, Taib NM, Rahim KA, et al
    Willingness to pay for hepatitis B vaccination in Selangor, Malaysia: A cross-sectional household survey.
    PLoS One. 2019;14:e0215125.
    PubMed     Text format     Abstract available
    
    
36. HANG PHAM TT, Le TX, Nguyen DT, Luu CM, et al
    Knowledge, attitudes and practices of hepatitis B prevention and immunization of pregnant women and mothers in northern Vietnam.
    PLoS One. 2019;14:e0208154.
    PubMed     Text format     Abstract available
    
    
37. PETRUZZIELLO A, Sabatino R, Loquercio G, Guzzo A, et al
    Correction: Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy.
    PLoS One. 2019;14:e0215559.
    PubMed     Text format     Abstract available
    
    

    
    Proc Natl Acad Sci U S A

38. IWAMOTO M, Saso W, Sugiyama R, Ishii K, et al
    Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization.
    Proc Natl Acad Sci U S A. 2019 Apr 5. pii: 1811064116.
    PubMed     Text format     Abstract available
    
    

    
    Science

39. COHEN J
    Forgotten no more.
    Science. 2018;362:984-987.
    PubMed     Text format    
    
    

    
    Vaccine

40. ECHEVARRIA D, Gutfraind A, Boodram B, Layden J, et al
    Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.
    Vaccine. 2019 Apr 5. pii: S0264-410X(19)30319.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: